This paper is in the following e-collection/theme issue:

Clinical Information and Decision Making (1656) mHealth in a Clinical Setting (680) Decision Support for Health Professionals (1338) Dementia and Cognitive Decline (590) Digital Health Reviews (1524) New Methods (1030) Research Instruments, Questionnaires, and Tools (665)

Published on in Vol 27 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/68454, first published .
Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Authors of this article:

Danko Jeremic1 Author Orcid Image ;   Juan D Navarro-Lopez1 Author Orcid Image ;   Lydia Jimenez-Diaz1 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Danko Jeremic   1 , PharmD, PhD ;   Juan D Navarro-Lopez   1 * , PharmD, PhD ;   Lydia Jimenez-Diaz   1 * , PharmD, PhD

1 Neurophysiology & Behavior Lab, Institute of Biomedicine (IB-UCLM) and Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain

*these authors contributed equally

Corresponding Author:

  • Lydia Jimenez-Diaz, PharmD, PhD
  • Neurophysiology & Behavior Lab
  • Institute of Biomedicine (IB-UCLM) and Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Faculty of Medicine of Ciudad Real
  • University of Castilla-La Mancha
  • Camino Moledores s/n
  • Ciudad Real, 13071
  • Spain
  • Phone: 34 926295300
  • Email: lydia.jimenez@uclm.es